CNBX - Cannabics' RCC-33 prolongs survival rate in mice inoculated with human colorectal cancer cells

Cannabics Pharmaceuticals (CNBX) announces results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells.Study results indicate a 35% prolonged survival rate in mice exposed to RCC-33 in comparison with sham control mice, as shown by Kaplan-Meier survival curve analysis, P-value = 0.08.The mean survival rate in the experimental group was 31 days from treatment initiation vs. 23 days in the control group.Cannabics plans to schedule a pre-IND meeting with the US FDA by next quarter and start Phase 1/2a trials by beginning of 2022.

For further details see:

Cannabics' RCC-33 prolongs survival rate in mice inoculated with human colorectal cancer cells